• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Surmodics Inc.

    3/19/25 4:00:48 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    SURMODICS INC

    (Name of Issuer)


    Common Stock, $0.05 par value

    (Title of Class of Securities)


    868873100

    (CUSIP Number)


    DAVID GOLDMAN
    GAMCO INVESTORS, INC., ONE CORPORATE CENTER
    RYE, NY, 10580
    9149215000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/12/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GAMCO INVESTORS, INC. ET AL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI FUNDS LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    392,575.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    392,575.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    392,575.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.8 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GAMCO Asset Management Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    119,100.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    119,100.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    119,100.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.8 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI & Co INVESTMENT ADVISERS, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    194,637.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    194,637.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    194,637.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.4 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI FOUNDATION, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    9,500.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    9,500.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    9,500.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GGCP, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    Associated Capital Group, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    2,300.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    2,300.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    2,300.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    868873100


    1 Name of reporting person

    GABELLI MARIO J
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.05 par value
    (b)Name of Issuer:

    SURMODICS INC
    (c)Address of Issuer's Principal Executive Offices:

    9924 W 74TH ST, EDEN PRAIRIE, MINNESOTA , 55344.
    Item 2.Identity and Background
    (a)
    This statement is being filed by one or more of the following persons: GGCP, Inc. (GGCP), GGCP Holdings LLC (GGCP Holdings), GAMCO Investors, Inc. (GBL), Associated Capital Group, Inc. (AC), Gabelli Funds, LLC (Gabelli Funds), GAMCO Asset Management Inc. (GAMCO), Teton Advisors, LLC (Teton Advisors), Keeley-Teton Advisors, LLC (Keeley-Teton), Gabelli & Company Investment Advisers, Inc. (GCIA), Morgan Group Holding Co., (MGH), G.research, LLC (G.research), MJG Associates, Inc. (MJG Associates), Gabelli Securities International (Bermuda) Limited (GSIL), Gabelli Foundation, Inc. (Foundation), Mario Gabelli, LICT and CIBL. Those of the foregoing persons signing this Schedule 13D are hereinafter referred to as the Reporting Persons.
    (b)
    GAMCO is a New York corporation and GBL and MGH are Delaware corporations, each having its principal business office at One Corporate Center, Rye, New York 10580. GGCP is a Wyoming corporation and AC and GCIA are Delaware corporations each having its principal business office 191 Mason Street, Greenwich, CT 06830. GGCP Holdings is a Delaware limited liability corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. G.research is a Delaware limited liability company having its principal officers at One Corporate Center, Rye, New York 10580. Gabelli Funds is a New York limited liability company having its principal business office at One Corporate Center, Rye, New York 10580. Teton Advisors is a Delaware limited liability company having its principal place of business at 189 Mason Street, Greenwich, CT 06830. Keeley-Teton Advisors is a Delaware limited liability company having its principal place of business at 141 W. Jackson Blvd., Chicago, IL 60604. MJG Associates is a Connecticut corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. The Foundation is a Nevada corporation having its principal offices at 165 West Liberty Street, Reno, Nevada 89501. LICT is a Delaware corporation having its principal place of business as 401 Theodore Fremd Avenue, Rye, New York 10580. CIBL, Inc. is a Delaware corporation having its principal place of business as 165 West Liberty Street, Suite 220, Reno, NV 89501.
    (c)
    GGCP makes investments for its own account and is the manager and a member of GGCP Holdings which is the controlling shareholder of GBL and AC. GBL, a public company whose stock is quoted on the OTCQX platform, is the parent company for a variety of companies engaged in the securities business, including certain of those named below. AC, a public company listed on the New York Stock Exchange, is the parent company for a variety of companies engaged in the securities business, including certain of those listed below. GAMCO, a wholly-owned subsidiary of GBL, is an investment adviser registered under the Investment Advisers Act of 1940, as amended (Advisers Act). GAMCO is an investment manager providing discretionary managed account services for employee benefit plans, private investors, endowments, foundations and others. GCIA, a wholly owned subsidiary of AC, is an investment adviser registered under the Advisers Act and serves as a general partner or investment manager to limited partnerships and offshore investment companies and other accounts. As a part of its business, GCIA may purchase or sell securities for its own account. GCIA or its relying advisers, act as a general partner or investment manager of a number of funds or partnerships, including Gabelli Associates Fund, L.P., Gabelli Associates Fund II, L.P., Gabelli Associates Limited, Gabelli Associates Limited II E, Gabelli Intermediate Credit Fund L.P., GAMA Select Plus Master Fund, Ltd., GAMCO Medical Opportunities L.P., and Gabelli Multimedia Partners, L.P. G.research is a wholly owned subsidiary of MGH. G.research, is a broker-dealer registered under the Securities Exchange Act of 1934, as amended (1934 Act), which may as a part of its business purchase and sell securities for its own account. Gabelli Funds, a wholly owned subsidiary of GBL, is a limited liability company. Gabelli Funds is an investment adviser registered under the Advisers Act which provides advisory services for The Gabelli Equity Trust Inc., The Gabelli Asset Fund, The Gabelli Growth Fund, The Gabelli Convertible and Income Securities Fund Inc., The Gabelli Value 25 Fund Inc., The Gabelli Small Cap Growth Fund, The Gabelli Equity Income Fund, The Gabelli ABC Fund, The Gabelli Global Content & Connectivity Fund, The Gabelli Gold Fund, Inc., The Gabelli Multimedia Trust Inc., The Gabelli Global Rising Income & Dividend Fund, The Gabelli Capital Asset Fund, The Gabelli International Growth Fund, Inc., The Gabelli Global Growth Fund, The Gabelli Utility Trust, The Gabelli Utilities Fund, The Gabelli Dividend Growth Fund, The Gabelli Focused Growth and Income Fund, The Comstock Capital Value Fund, The Gabelli Dividend and Income Trust, The Gabelli Global Utility & Income Trust, The GAMCO Global Gold, Natural Resources, & Income Trust, The GAMCO Natural Resources, Gold & Income Trust, The GDL Fund, Gabelli Enterprise Mergers & Acquisitions Fund, The Gabelli ESG Fund, Inc., The Gabelli International Small Cap Fund, The Gabelli Healthcare & Wellness Rx Trust, The Gabelli Global Small and Mid Cap Value Trust, Gabelli Merger Plus+ Trust Plc, The Gabelli Global Financial Services Fund, The Gabelli Global Mini Mites Fund, The Gabelli Media Mogul Fund, The Gabelli Pet Parents Fund, The Gabelli U.S. Treasury Money Market Fund, Bancroft Fund Ltd. and Ellsworth Growth & Income Fund Ltd., Gabelli Growth Innovators ETF, Gabelli Love Our Planet & People ETF, Gabelli Automation ETF, Gabelli Commercial Aerospace & Defense ETF, Gabelli Financial Services Opportunities ETF (collectively, the Funds), which are registered investment companies. Gabelli Funds is also the investment adviser to The GAMCO International SICAV (sub-funds GAMCO Merger Arbitrage and GAMCO All Cap Value), a UCITS III vehicle. Teton Advisors, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The TETON Westwood Mighty Mitessm Fund, The TETON Convertible Securities Fund, The Teton Westwood Balanced Fund, and The TETON Westwood Equity Fund. The TETON Westwood Mighty Mites Fund and the Teton Convertible Securities Fund are subadvised by Gabelli Funds, and their holdings are included in this filing. Keeley-Teton, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The Teton Westwood Smallcap Equity Fund, The Keeley Small Cap Dividend Value Fund, The Keeley Small-Mid Cap Value Fund, and The Keeley Mid Cap Dividend Value Fund, as well as to institutional and individual clients. MJG Associates provides advisory services to private investment partnerships and offshore funds. Mario Gabelli is the sole shareholder, director and employee of MJG Associates. MJG Associates is the Investment Manager of Gabelli International Limited and Gabelli Fund, LDC. Mario J. Gabelli is the general partner of Gabelli Performance Partnership, LP. The Foundation is a private foundation. Mario Gabelli is the Chairman, a Trustee and the Investment Manager of the Foundation. Elisa M. Wilson is the President of the Foundation. LICT is a holding company with operating subsidiaries engaged primarily in the rural telephone industry. LICT actively pursues new business ventures and acquisitions. LICT makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is the Chief Executive Officer, a director, and substantial shareholder of LICT. CIBL is a holding company with interest in telecommunications operations, primarily in the rural telephone industry. CIBL actively pursues new business ventures and acquisitions. CIBL makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is a director, and substantial shareholder of CIBL. Mario Gabelli is the controlling stockholder, co-Chief Executive Officer and a director of GGCP and Chairman and Chief Executive Officer of GBL. He is the Executive Chairman of AC. Mario Gabelli is also a member of GGCP Holdings. Mario Gabelli is the controlling shareholder of MGH and indirectly of Teton Advisors and Keeley-Teton Advisors.
    (d)
    Not applicable.
    (e)
    Not applicable.
    (f)
    United States
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Reporting Persons used an aggregate of approximately $23,957,840 to purchase the Securities reported as beneficially owned in Item 5. GAMCO and Gabelli Funds used approximately $3,203,076 and $12,742,034, respectively, of funds that were provided through the accounts of certain of their investment advisory clients (and, in the case of some of such accounts at GAMCO, may be through borrowings from client margin accounts) in order to purchase the Securities for such clients. GCIA used approximately $7,498,564 of client funds to purchase the Securities reported by it. AC used approximately $96,801 of working capital to purchase the Securities reported by it. Foundation used approximately $417,365 of working capital to purchase the Securities reported by it.
    Item 4.Purpose of Transaction
     
    Each of the Reporting Persons has purchased and holds the Securities reported by it for investment for one or more accounts over which it has shared, sole, or both investment and/or voting power, for its own account, or both. The Reporting Persons are engaged in the business of securities analysis and investment. The Reporting Persons analyze the operations, capital structure and markets of companies in which they invest, including the Issuer, on a continuous basis through analysis of documentation and discussions with knowledgeable industry and market observers and with representatives of such companies (often at the invitation of management). As a result of these analytical activities one or more of the Reporting Persons may issue analysts reports, participate in interviews or hold discussions with third parties, with management or with Directors in which the Reporting Person may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder values. Such suggestions or positions may relate to one or more of the transactions specified in clauses (a) through (j) of Item 4 of Schedule 13D including, without limitation, such matters as disposing of one or more businesses, selling the company or acquiring another company or business, changing operating or marketing strategies, adopting or not adopting, certain types of anti-takeover measures and restructuring the company capitalization or dividend policy. Each of the Reporting Persons intends to adhere to the foregoing investment philosophy with respect to the Issuer. However, none of the Reporting Persons intends to seek control of the Issuer or participate in the management of the Issuer, and any Reporting Person that is registered as an investment company under the Company Act will participate in such a transaction only following receipt of an exemption from the SEC under Rule 17d-1 under the Company Act, if required, and in accordance with other applicable law. In pursuing this investment philosophy, each Reporting Person will continuously assess the Issuers business, financial condition, results of operations and prospects, general economic conditions, the securities markets in general and those for the Issuers securities in particular, other developments and other investment opportunities, as well as the investment objectives and diversification requirements of its shareholders or clients and its fiduciary duties to such shareholders or clients. Depending on such assessments, one or more of the Reporting Persons may acquire additional Securities or may determine to sell or otherwise dispose of all or some of its holdings of Securities. Although the Reporting Persons share the same basic investment philosophy and although most portfolio decisions are made by or under the supervision of Mario Gabelli, the investment objectives and diversification requirements of various clients differ from those of other clients so that one or more Reporting Persons may be acquiring Securities while others are disposing of Securities. With respect to voting of the Securities, the Reporting Persons have adopted general voting policies relating to voting on specified issues affecting corporate governance and shareholder values. Under these policies, the Reporting Persons generally vote all securities over which they have voting power in favor of cumulative voting, financially reasonable golden parachutes, one share one vote, management cash incentives and pre-emptive rights and against greenmail, poison pills, supermajority voting, blank check preferred stock and super-dilutive stock options. Exceptions may be made when management otherwise demonstrates superior sensitivity to the needs of shareholders. In the event that the aggregate voting position of all Reporting Persons exceeds 25% of the total voting position of the Issuer, one or more of the filing persons may transfer voting and/or dispositive power over shares to independent committees of directors or the owners of such shares. Such committees vote and/or consider disposition of such shares independently of the Reporting Persons. Each of the Covered Persons who is not a Reporting Person has purchased the Securities reported herein as beneficially owned by him for investment for his own account or that of one or more members of his immediate family. Each such person may acquire additional Securities or dispose of some or all of the Securities reported herein with respect to him. Other than as described above, none of the Reporting Persons and none of the Covered Persons who is not a Reporting Person has any present plans or proposals which relate to or would result in any transaction, change or event specified in clauses (a) through (j) of Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    The aggregate number of Securities to which this Schedule 13D relates is 718,112 shares, representing 5.02% of the 14,295,998 shares outstanding as reported in the Issuer's most recently filed Form 10-Q for the quarterly period ended December 31, 2024. The Reporting Persons beneficially own those Securities as follows: GAMCO 119,100 shares 0.83%, Gabelli Funds 392,575 shares 2.75%, GCIA 194,637 shares 1.36%, AC 2,300 shares 0.02% and Foundation 9,500 shares 0.07%
    (b)
    Each of the Reporting Persons and Covered Persons has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition of the Securities reported for it, either for its own benefit or for the benefit of its investment clients or its partners, as the case may be, except that (i) Gabelli Funds has sole dispositive and voting power with respect to the shares of the Issuer held by the Funds so long as the aggregate voting interest of all joint filers does not exceed 25% of their total voting interest in the Issuer and, in that event, the Proxy Voting Committee of each Fund shall respectively vote that Funds shares, (ii) at any time, the Proxy Voting Committee of each such Fund may take and exercise in its sole discretion the entire voting power with respect to the shares held by such fund under special circumstances such as regulatory considerations, and (iii) the power of Mario Gabelli, AC, GBL, and GGCP is indirect with respect to Securities beneficially owned directly by other Reporting Persons.
    (c)
    Information with respect to all transactions in the Securities which were effected during the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by each of the Reporting Persons and Covered Persons is set forth below: DATE SHARES PURCHASED PRICE /SOLD GABELLI & COMPANY INVESTMENT ADVISERS, INC. GABELLI ASSOCIATES FUND II 3/12/2025 250 26.7249 3/11/2025 450 27.4693 3/10/2025 200 28.0316 3/7/2025 300 29.3257 3/6/2025 200 29.6202 2/6/2025 500 33.9779 2/4/2025 200 33.7541 2/3/2025 600 34.0644 1/31/2025 650 34.5414 1/30/2025 200 35.6195 1/28/2025 700 36.3166 1/22/2025 300 37.1479 GABELLI ASSOCIATES FUND 3/12/2025 600 26.7249 3/11/2025 1,400 27.4693 3/10/2025 550 28.0316 3/7/2025 750 29.3257 3/6/2025 750 29.6202 3/3/2025 500 31.0725 2/6/2025 1,500 33.9779 2/4/2025 650 33.7541 2/3/2025 1,650 34.0644 1/31/2025 1,850 34.5414 1/30/2025 550 35.6195 1/28/2025 200 36.3166 GABELLI ASSOCIATES LIMITED II E 3/12/2025 450 26.7249 3/11/2025 850 27.4693 3/10/2025 400 28.0316 3/7/2025 450 29.3257 3/6/2025 500 29.6202 3/3/2025 350 31.0725 2/6/2025 900 33.9779 2/4/2025 450 33.7541 2/3/2025 1,000 34.0644 1/31/2025 550 34.5414 1/30/2025 350 35.6195 1/28/2025 1,300 36.3166 1/22/2025 450 37.1479 GABELLI ASSOCIATES LIMITED 3/12/2025 1,200 26.7249 3/11/2025 2,600 27.4693 3/10/2025 1,100 28.0316 3/7/2025 1,400 29.3257 3/6/2025 1,450 29.6202 3/3/2025 1,150 31.0725 2/6/2025 2,750 33.9779 2/4/2025 1,300 33.7541 2/3/2025 3,050 34.0644 1/31/2025 3,750 34.5414 1/30/2025 1,100 35.6195 1/28/2025 3,700 36.3166 1/23/2025 100 36.7000 1/22/2025 1,300 37.1479 GABELLI FOUNDATION, INC. 3/10/2025 -600 28.2250 2/12/2025 -500 34.0638 GABELLI FUNDS, LLC COMSTOCK CAPITAL VALUE FUND 3/12/2025 250 26.7249 3/11/2025 250 27.4693 2/3/2025 500 34.0644 GABELLI ENTERPRISE M&A FUND 2/7/2025 -300 33.8977 1/29/2025 -2,200 35.6352 GAMCO MERGER ARBITRAGE UCITS 3/12/2025 1,950 26.7249 3/11/2025 3,750 27.4693 3/10/2025 2,550 28.0316 3/7/2025 2,266 29.3257 3/6/2025 1,750 29.6202 3/3/2025 2,700 31.0725 2/6/2025 3,700 33.9779 2/4/2025 2,000 33.7541 2/3/2025 4,700 34.0644 1/31/2025 2,300 34.5414 1/28/2025 5,150 36.3166 GABELLI MERGER PLUS+ TRUST 3/12/2025 300 26.7249 3/11/2025 700 27.4693 3/10/2025 200 28.0316 3/7/2025 450 29.3257 3/6/2025 350 29.6202 3/3/2025 300 31.0725 2/6/2025 650 33.9779 2/4/2025 400 33.7541 2/3/2025 800 34.0644 1/31/2025 900 34.5414 1/30/2025 300 35.6195 1/28/2025 950 36.3166 1/22/2025 450 37.1479 GABELLI SMALL CAP GROWTH FUND 2/20/2025 -500 34.2500 GAMCO ASSET MANAGEMENT INC. 3/18/2025 1,500 28.9800 3/11/2025 -1,200 27.3547 3/10/2025 1,400 28.8600 3/7/2025 5,000 29.5000 2/20/2025 -800 34.2500 2/18/2025 -500 34.1800 2/14/2025 -500 34.1802 2/11/2025 -400 34.4700 2/10/2025 -500 34.4100 2/7/2025 -600 33.8617 2/5/2025 -700 34.1015 2/4/2025 -500 34.1270 2/3/2025 -5,848 34.8921 1/30/2025 -1,000 35.6040 1/24/2025 -500 37.9500
    (d)
    The investment advisory clients of, or partnerships managed by, GAMCO, Gabelli Funds, Teton Advisors and MJG Associates have the sole right to receive and, subject to the notice, withdrawal and/or termination provisions of such advisory contracts and partnership arrangements, the sole power to direct the receipt of dividends from, and the proceeds of sale of, any of the Securities beneficially owned by such Reporting Persons on behalf of such clients or partnerships. Except as noted, no such client or partnership has an interest by virtue of such relationship that relates to more than 5% of the Securities.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The powers of disposition and voting of Gabelli Funds, Teton Advisors, GAMCO, GCIA and MJG Associates with respect to Securities owned beneficially by them on behalf of their investment advisory clients, and of MJG Associates and GCIA with respect to Securities owned beneficially by them on behalf of the partnerships or corporations which they directly or indirectly manage, are held pursuant to written agreements with such clients, partnerships and funds.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    GAMCO INVESTORS, INC. ET AL
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:GENERAL COUNSEL
    Date:03/19/2025
     
    GABELLI FUNDS LLC
     
    Signature:DAVID GOLDMAN
    Name/Title:GENERAL COUNSEL
    Date:03/19/2025
     
    GAMCO Asset Management Inc.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:03/19/2025
     
    GABELLI & Co INVESTMENT ADVISERS, INC.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:03/19/2025
     
    GABELLI FOUNDATION, INC.
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:03/19/2025
     
    GGCP, INC.
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:03/19/2025
     
    Associated Capital Group, Inc.
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:CHIEF LEGAL OFFICER
    Date:03/19/2025
     
    GABELLI MARIO J
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:03/19/2025
    Get the next $SRDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Financials

    Live finance-specific insights

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

      1/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

      6/27/23 7:05:00 AM ET
      $KRMD
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

      European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the Eur

      4/22/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/20/25 4:12:56 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:22:54 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:20:51 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surmodics upgraded by Lake Street with a new price target

      Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

      3/7/25 8:21:43 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics upgraded by Needham with a new price target

      Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

      6/13/23 7:48:05 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics downgraded by Needham

      Needham downgraded Surmodics from Buy to Hold

      2/13/23 7:24:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    SEC Filings

    See more
    • SEC Form SD filed by Surmodics Inc.

      SD - SURMODICS INC (0000924717) (Filer)

      5/20/25 5:30:03 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surmodics Inc.

      SCHEDULE 13G/A - SURMODICS INC (0000924717) (Subject)

      5/13/25 4:44:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Surmodics Inc.

      10-Q - SURMODICS INC (0000924717) (Filer)

      4/30/25 7:55:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/14/24 3:36:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/6/24 1:30:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      10/23/24 10:43:41 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care